Zura Bio shows near-term bullish technical momentum, but a cash-burning, sub-floor quality profile, a persistent earnings-miss streak, and a rejected analyst price target all argue for skepticism on the clinical-stage biotech.
Thesis pillars
- Quality Below Floor Cash Burning Biotech→Stable
- Consistent Earnings Misses→Stable
- Analyst Target Data Quality Rejection→Stable
- +1 more pillar — see the Why tab for full reasoning
Zura Bio Limited (ZURA) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $5.18: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 9.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Zura Bio is a clinical-stage biotechnology company developing in-licensed antibody therapies for autoimmune and inflammatory diseases, led by tibulizumab, a bispecific IL-17A/BAFF antibody in two ongoing Phase 2 trials for hidradenitis suppurativa and diffuse cutaneous systemic... Read more
Sell if holding. Engine safety override at $5.18: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 9.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news boost analyst 0.70, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Zura Bio Limited
About Zura Bio Limited
Zura Bio's clinical pipeline centers on tibulizumab, a bispecific antibody neutralizing both IL-17A and BAFF, now in two global Phase 2 trials: TibuSHIELD in hidradenitis suppurativa, expanded to approximately 225 participants with topline data expected in the fourth quarter of 2026, and TibuSURE in diffuse cutaneous systemic sclerosis, with data expected in the first half of 2027. The company has in-licensed two additional clinical-stage candidates, crebankitug and torudokimab, from Pfizer and Eli Lilly, respectively, but has not completed any Phase 2 or Phase 3 trial and has generated no product revenue to date.
Zura Bio has no approved products and no revenue; its entire clinical portfolio was in-licensed rather than internally discovered, with tibulizumab and torudokimab originally developed by Eli Lilly and crebankitug by Pfizer, each evaluated in earlier-stage trials by those companies before Zura acquired development rights. The company outsources all manufacturing to third-party contract manufacturers rather than operating its own facilities, having produced three batches of tibulizumab drug substance in the Netherlands and three batches of finished drug product in Italy, with additional batches planned for 2026; Zura's license from Lilly also covers the underlying drug-substance manufacturing process and associated analytical testing. Crebankitug and torudokimab remain in a holding pattern, with the company evaluating potential future development strategies for both rather than actively advancing them through new trials, concentrating near-term operational and financial resources on tibulizumab's two ongoing Phase 2 programs.
Show full overview
Zura's own risk factors frame its dependency in structural terms distinct from clinical-trial risk alone: the company says it depends on license agreements with Pfizer and Eli Lilly to use the patents, know-how, and technology underlying all three of its product candidates, and that termination of those rights or a failure to comply with license obligations could materially harm its ability to develop or commercialize tibulizumab, crebankitug, or torudokimab. That places Zura's entire pipeline value at the intersection of two separate large-pharma relationships it does not control, compounding the ordinary binary risk of Phase 2 clinical failure with the risk that a licensor dispute alone could cut off development rights regardless of trial outcomes.
See also: Healthcare · Biotechnology
From Zura Bio Limited's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-08Recent Developments — Zura Bio Limited
Latest news
- NEWS William Blair Initiates Coverage On Zura Bio with Outperform Rating — benzinga Jul 8, 2026 positive
- NEWS Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy — benzinga Jul 8, 2026 positive
- NEWS Wedbush Reiterates Outperform on Zura Bio, Maintains $15 Price Target — benzinga Jul 1, 2026 positive
- NEWS Zura Bio Completes Enrollment In Phase 2 TibuSHIELD Trial of Tibulizumab in Adults With HS — benzinga Jun 29, 2026 positive
Generated 2026-07-08T21:03:53Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineZB Assets (tibulizumab, torudokimab, crebankitug)10-K Item 1A: 'We are substantially dependent on the success of the ZB Assets, and our ongoing and anticipated clinical trials of the ZB Assets may not be successful.'
- HIGHcounterpartyPfizer and Eli Lilly license agreements10-K Item 1A: 'We depend on license agreements with Pfizer Inc. and their wholly owned subsidiaries (“Pfizer”) and Eli Lilly and Company and their wholly owned subsidiaries (“Lilly”) to permit us to use certain patents, know-how and technology.'
Material Events(8-K, last 90d)
- 2026-04-23Item 5.02MEDIUMCFO, Principal Financial Officer and Principal Accounting Officer Eric Hyllengren separated from the company effective April 20, 2026, not related to financial results or disagreements. Marlyn Mathew was appointed Principal Accounting and Financial Officer the same day.SEC filing →
- 2026-05-22Item 5.02LOWDirector Someit Sidhu resigned from the board effective May 21, 2026, not due to any disagreement with the company. No successor named.SEC filing →
- 2026-06-18Item 5.02LOWAt the June 17, 2026 annual meeting, shareholders approved an amended and restated 2023 Equity Incentive Plan. Routine annual meeting business, no departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.18: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 9.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $5.11. Score 5.5/10, moderate confidence.
Take-profit target: $13.63 (+148.3% upside). Prior stop was $5.11. Stop-loss: $5.11.
Concentration risk — Pipeline: ZB Assets (tibulizumab, torudokimab, crebankitug); Concentration risk — Counterparty: Pfizer and Eli Lilly license agreements; Quality below floor (1.2 < 4.0).
Zura Bio Limited trades at a P/E of N/A (forward -53.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
14 analysts cover ZURA with a consensus score of 4.4/5. Average price target: $16.
What does Zura Bio Limited do?Zura Bio is a clinical-stage biotechnology company developing in-licensed antibody therapies for autoimmune and...
Zura Bio is a clinical-stage biotechnology company developing in-licensed antibody therapies for autoimmune and inflammatory diseases, led by tibulizumab, a bispecific IL-17A/BAFF antibody in two ongoing Phase 2 trials for hidradenitis suppurativa and diffuse cutaneous systemic sclerosis. The company also holds rights to crebankitug (IL-7Rα) and torudokimab (IL-33), in-licensed from Pfizer and Eli Lilly respectively, but has not completed any Phase 2 or Phase 3 trials, generated no product revenue, and says it is substantially dependent on the success of these three assets.